Exbivirumab
Exbivirumab
Exbivirumab (pronunciation: eks-bi-vi-ru-mab) is a monoclonal antibody designed for the treatment of various cancer types. It is a type of biological therapy that targets specific proteins on cancer cells to inhibit their growth and spread.
Etymology
The term "Exbivirumab" is derived from the International Nonproprietary Names (INN) system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, a type of protein made in the lab designed to bind to specific substances in the body.
Usage
Exbivirumab is used in the treatment of various types of cancer, including melanoma, lung cancer, and colorectal cancer. It works by binding to specific proteins on the surface of cancer cells, inhibiting their growth and spread.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Biological therapy: Treatment that uses the patient's immune system to fight cancer.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- Melanoma: The most serious type of skin cancer.
- Lung cancer: A type of cancer that begins in the lungs.
- Colorectal cancer: A type of cancer that begins in the colon or the rectum.
External links
- Medical encyclopedia article on Exbivirumab
- Wikipedia's article - Exbivirumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski